V0018

Pierre Fabre Medicament · Phase 2 active Small molecule

At a glance

Generic name	V0018
Sponsor	Pierre Fabre Medicament
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assessment of V0018 2.5 mg Effect on Craving (PHASE2)
Assessment of V0018 1.5 mg Effect on Craving (PHASE2)
Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

V0018 CI brief — competitive landscape report
V0018 updates RSS · CI watch RSS
Pierre Fabre Medicament portfolio CI